May
SOM Biotech announced that it has signed a licensing agreement with the University of Minnesota. This license agreement follows the completion of research under a sponsored research agreement (SRA) signed in 2019, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular …
Feb
Today is Rare Disease Day 2022! At SOM Biotech we recognize the importance of raising awareness and progressing scientific research in the field of Rare Diseases. You can see our publications supporting rare Disease Day on LinkedIn and Twitter. Join us and get involved today: https://www.rarediseaseday.org/#.
SOM Biotech (“SOM” or the “Company”), a clinical-stage biopharmaceutical company with a proprietary AI-based drug discovery technology and a focus on neurological orphan diseases, today announces that it has signed a letter of intent with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, regarding a potential exclusive distribution agreement for the commercialization of SOM3355 to …
Oct
~SOM3355 has the potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease~ SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food …
Oct
~Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile~ ~SOM3355 discovered through SOM Biotech’s proprietary artificial intelligence-based computational technology SOMAI PRO~ SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of …